All News

2018

November

Media Release / Nov 16, 2018

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Read More
Media Release / Nov 16, 2018

Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

Read More
Media Release / Nov 13, 2018

Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London

Read More
Media Release / Nov 11, 2018

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Read More
Media Release / Nov 05, 2018

Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms

Read More
Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More
Media Release / Nov 02, 2018

Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)

Read More
Media Release / Oct 29, 2018

Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH

Read More
Media Release / Oct 27, 2018

Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More